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Introduction. Retroperitoneal sarcomas are uncommon large malignant tumors. Methods. Forty-one consecutive patients with
localized retroperitoneal sarcoma were retrospectively studied. Results. Median age was 58 years (range 20–91 years). Median
tumor size was 17.5cm (range 4–41cm). Only 2 tumors were <5cm. Most were liposarcoma (44%) and high-grade (59%). 59%
were stage 3 and the rest was stage 1. Median followup was 10 months (range 1–106 months). Thirty-eight patients had an initial
complete resection; 15 (37%) developed recurrent sarcoma and 12 (80%) had a second complete resection. Patients with an initial
complete resection had a 5-year survival of 46%. For all patients, tumor grade aﬀected overall survival (P = .006). Complete
surgical resection improved overall survival for high-grade tumors (P = .03). Conclusions. Tumor grade/stage and complete
surgicalresectionforhigh-gradetumorsareimportantprognosticvariables.Radiationtherapyorchemotherapyhadnosigniﬁcant
impact on overall or recurrence-free survival. Complete surgical resection is the treatment of choice for patients with initial and
locally recurrent retroperitoneal sarcoma.
Copyright © 2009 Sepideh Gholami et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Sarcomas are uncommon malignant tumors arising from
mesenchymal tissue. Retroperitoneal sarcomas account for
approximately 10% of soft tissue sarcomas and less than
1% of all malignant neoplasms [1, 2]. The common histo-
logic types are liposarcoma, leiomyosarcoma, and malignant
ﬁbrous histiocytoma [3–6].
Due to minimal early symptoms, retroperitoneal sarco-
mas are often diagnosed when the tumors are large and
involve surrounding organs. En bloc surgical resection is
the treatment of choice. This has been described recently
as compartmental resection in which there is a systematic
removal of adjacent organs to obtain a rim of normal
tissue surrounding the tumor [7]. Compartmental resection
has been reported to have a 3-fold lower rate of sarcoma
recurrence in a recent study [7]. In general, surgery has a
reported complete resection rate between 65–99% [4, 5].
However, complete resection may be diﬃcult to achieve,
due to involvement of surrounding vital structures. The
completenessofsurgicalresectionisanimportantprognostic
variable as it has been shown to improve survival [7–9].
Incomplete resection is ineﬀective [5, 8].
In contrast to patients with extremity sarcomas, the
eﬃcacy of adjuvant radiation therapy for retroperitoneal
sarcomas is less clear. One of the major limiting factors
is diﬃculty in delivering suﬃcient radiation dose because
of toxicity to adjacent organs including bowel, kidneys,
liver, and spinal cord [10, 11]. Two randomized trials have
demonstrated that adjuvant radiation therapy results in a
signiﬁcant reduction in local recurrence rates in superﬁcial
trunk and extremity sarcomas [11, 12]. One randomized
trial using intraoperative radiation has also shown an
improvement in local control of retroperitoneal sarcomas
[10]. In addition, several retrospective and prospective
studies suggest improved local control with the use of2 Sarcoma
adjuvant radiation therapy for retroperitoneal sarcomas
[13–15]. Catton et al. showed that postoperative radiation
therapy with doses of >35Gy after complete resection of the
tumor delayed, although did not prevent, local recurrence
when compared to historical controls [13]. Fein et al.
demonstrated a lower local failure rate in patients with
retroperitoneal sarcoma who received adjuvant radiation
therapy [16]. However, a recent study by Ballo et al. failed
to show any improvement in local control with external
beamorintra-operativeradiationtherapy[3].Giventhehigh
relapse rate, some have oﬀered patients with retroperitoneal
sarcoma adjuvant chemotherapy; however, its role remains
unproven and controversial. The purpose of the current
study was to review our experience in the management of
retroperitoneal soft tissue sarcomas and identify important
prognostic factors for local control and survival.
2.MaterialsandMethods
2.1. Patient Material. Between January 1996 and 2007,
102 consecutive patients with a presumptive diagnosis of
retroperitoneal sarcoma were referred to Stanford Hospital
and Clinics. Among these, eight patients were found to
have gastrointestinal stromal tumors, one a desmoplastic
round small cell tumor, and ten non-cancerous disease.
Thirty-four patients had a previous surgical resection at
another institution, and two had medical contraindica-
tions to major surgery. Six patients had distant metastatic
disease. The remaining forty one patients had previously
untreated localized retroperitoneal sarcoma and comprise
the cohort of this study. Medical records, including clinic
notes, radiographic, operative, and pathology reports were
reviewed. The association between patient demographics,
tumor characteristics, treatment variables, and outcomes
was assessed. Patient demographics included sex, age, and
duration of symptoms. Tumors were characterized based on
histopathologic type, size in greatest dimension, grade, and
pathological stage. We used the sixth edition of the American
Joint Committee on Cancer (AJCC) staging system for soft
tissue sarcomas. It categorizes stages 1–4 based on tumor
size, depth, grade, lymph node, and distant metastases [17].
Treatment variables analyzed included complete (R0/R1)
versus incomplete resection (R2) and adjuvant therapy. The
use of radiation therapy and chemotherapy, recommended
byamultidisciplinaryteam,wasalsoassessed.Thisstudywas
approvedbytheHumanandSubjectsResearchCommitteeat
Stanford University School of Medicine.
2.2. Statistical Analysis. Statistical analysis was performed
with SAS software (version 9.1.3 sp4, SAS institution).
Overall and disease-free survival was calculated. Date of
diagnosis was deﬁned as the time of initial tissue diagnosis.
Local recurrence was deﬁned as biopsy proof of tumor
recurrence at the primary tumor site. Distant recurrence was
deﬁned as recurrent tumor at a site distant from the primary
tumor.Overallsurvivalwascalculatedfromtimeofdiagnosis
to time of last followup or death. Deaths were conﬁrmed by
an internet-based search via the Social Security Death Index
Table 1: Demographic and tumor characteristics of 41 patients
with primary retroperitoneal sarcoma who underwent surgical
resection at Stanford Hospital from 1996 to 2007.
Variable N %o ft o t a l
Sex
Female 18 44
Male 23 56
Age
<55 years 16 39
>55 years 25 61
Duration of symptoms
<6m o n t h s 2 5 6 1
>6m o n t h s 1 1 2 7
Unkown 5 12
Histological subtype
Liposarcoma 22 54
Leiomyosarcoma 7 17
Malignant ﬁbrous histiocytoma 4 10
Other 8 19
Tumor size (maximum diameter)
<5cm 2 5
5–10cm 4 10
10–20cm 18 44
>20cm 17 41
Tumor grade
Low 17 41
High 24 59
(http://ssdi.rootsweb.com). First recurrence was used as the
endpointfordisease-freesurvival.Kaplan-Meiermethodand
the log-rank test were utilized for univariate analysis and
comparison of studied variables. The Cox-regression pro-
portional hazards model was used for multivariate analysis
of prognostic factors signiﬁcant in the univariate analysis.
All P-values recorded are two-sided and a P-value <.05 was
considered statistically signiﬁcant.
3. Results
3.1. Patient and Tumor Characteristics. Table 1 summarizes
the demographic characteristics of 41 patients with primary
retroperitoneal sarcoma included in this study. Twenty-three
(56%) were men and 18 (44%) woman. Median age was
58 years (range 20–91 years). Twenty-ﬁve patients (61%)
reported symptoms of less than 6 months duration and
11 (27%) had symptoms for longer periods of time. Five
patients did not have a record of symptoms. Presenting
symptoms included pain (n = 21.51%), mass/abdominal
distention (n =12.29%), constitutional symptoms (n = 3),
and others (n = 5). Liposarcoma was the most common
histological type (54%), followed by leiomyosarcoma (17%).
Median tumor size was 17.5cm (range 4–41cm); 59% of
the sarcomas were high grade. Seventeen patients (41%) had
stage1(low-gradesarcomas,<5cmwithoutmetastases),andSarcoma 3
Table 2: Initial treatment characteristics of 41 patients with
primary retroperitoneal sarcoma who underwent surgical resection
at Stanford Hospital from 1996 to 2007.
Variable N %o ft o t a l
Resection
R0/R1 38 93
R2 3 7
Contiguous organs resected
Yes 28 68
No 13 32
Radiation therapy
Preoperative 1 2
Intraoperative/postoperative 15 37
Both (preoperative and postoperative) 3 7
None 22 54
Chemotherapy
Neoadjuvant 5 12
Adjuvant 2 5
Both 1 2
None 33 81
24 (59%) had stage 3 (high-grade sarcomas, >5cm without
metastases) disease. Median followup was 10 months (range
1–106 months).
3.2. Treatment
3.2.1. Surgery. All patients underwent abdominal retroperi-
toneal exploration using an open approach. A total of
67 surgical procedures were performed in 41 patients; 18
patients underwent multiple surgical procedures. At time
of resection, 38 patients (93%) had a complete resection
with negative macroscopic margins (R0/R1) (Table 2). The
magnitude of surgery was signiﬁcant because we tried to
remove normal structures that were adjacent to the tumor.
Sixty-eight percent had one or more contiguous organs
removed to achieve a complete resection (kidney n = 18,
colon n = 14, small intestine n = 6, spleen n = 4,
pancreas n = 4, rectum/anus n = 3, liver n = 2, bladder
n = 1, stomach n = 1, prostate n = 1, gallbladder
n = 1). Morbidity rate was 19%. Complications included
infection (n = 5), anastomotic leak (n = 2), post-operative
hemorrhage (n = 2), small bowel obstruction (n = 2), and
myocardial infarction (n = 2). Mortality rate was 2%.
Tumor recurred in ﬁfteen patients (37%), with recurrent
site local (n = 10), distant (n = 2), and both local
and distant (n = 3). Of these, 12 (80%) underwent re-
exploration and a second complete resection was achieved
in all patients (100%). Ninety-three percent of patients had
complete resection of the retroperitoneal sarcoma. Rates
of complete resection were 100%, 86%, and 100% for the
1st, 2nd, and 3rd recurrences, respectively. CT imaging was
able to accurately predict those who could have all tumor
removed.
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Figure 1: Overall survival of 41 patients with initial resection of
primary retroperitoneal sarcoma.
3.2.2. Adjuvant Therapy. Nineteen (46%) patients had radi-
ation therapy with their initial surgery, 10 (83%) with their
second or third surgical resection. All patients with either R1
or R2 resection received adjuvant radiation therapy, whereas
patients with R0 resections did not.
Radiation therapy with the initial surgical resection
includedeitherpreoperativeradiationtherapy(n = 1),intra-
operative or postoperative radiation therapy (n = 15), or a
combination of both (n = 3). Post-operative external beam
radiation (n = 6), intraoperative radiation (IORT) (n = 8),
or both treatment modalities (n = 5) were administered.
IORT dose was commonly 12.5Gy and external beam
radiation dose ranged from 45–50Gy [17]. Eight patients
(20%) also received neoadjuvant or adjuvant chemotherapy,
including doxorubicin, ifosfamide, and mesna.
3.3. Overall Survival. Median overall survival for the 41
patients was 3.9 years. Estimated 2-year and 5-year sur-
vival was 69% and 46%, respectively (Figure 1). Gender,
age, length of symptoms, histological type, and size of
primary tumor did not signiﬁcantly inﬂuence overall sur-
vival (Table 3). Tumor grade signiﬁcantly impacted overall
survival (Figure 2). Overall median survival for low-grade
tumors was 6.1 years compared to 3.6 years for high-grade
tumors (P = .05). Estimated 5-year survival for low-
grade tumors versus high-grade tumors was 100% and 26%,
respectively (Figure 2). When we included low-grade sarco-
mas, complete surgical resection of tumor did not improve
overall survival. However, in a subset analysis including
patients with only high-grade sarcomas, complete tumor
resection improved overall survival. Adjuvant radiation or
chemotherapy with initial surgery resection had no eﬀect on
overall survival. By multivariate analysis, only tumor grade
and complete sarcoma resection for high-grade sarcomas
aﬀected overall survival.
3.4. Recurrence-Free Survival. 4 (10%) patients developed
distant metastases during subsequent followup such that
most tumor recurrences were local. For patients with an
initial complete resection (n = 38), median local recurrence-
free survival was 1.65 years. Estimated 2-year and 5-year4 Sarcoma
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Figure 2: Sarcoma-speciﬁc survival of same 41 patients divided by
tumor grade (low grade versus high grade).
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Figure 3: Disease-free survival of 38 patients who underwent
complete initial resection of the primary retroperitoneal tumor.
recurrence-free survival for patients with complete resec-
tions was 44% and 18%, respectively (Figure 3). Duration
of symptoms had a signiﬁcant impact on recurrence-free
survival (Table 4). Patients reporting >6 months duration of
symptoms at time of presentation had a shorter recurrence-
free survival compared to patients with <6 months of
symptoms (0.99 versus 3.9 years, P = .02). Adjuvant
chemotherapy and radiation therapy did not signiﬁcantly
aﬀect recurrence-free survival.
4. Discussion
Patients with retroperitoneal sarcomas tend to be diagnosed
late when they have a very large tumor burden. This is the
ﬁrst study that demonstrates that duration of symptoms is
inversely proportional to prognosis. This means that patients
who have symptoms for longer periods of time without
a diagnosis do worse and have a shorter recurrence-free
survival. As other studies have shown, gross total surgical
resection is the mainstay of treatment for retroperitoneal
sarcoma [5, 7]. As expected, low-grade tumors have a
better prognosis than high-grade tumors. For high-grade
tumorscompleteresectiondidimprovesurvivalcomparedto
Table 3: Univariate analysis of prognostic factors for overall
survival in 41 patients with primary retroperitoneal sarcoma.
Variable N 5-year survival (%) P-value
Sex 0.89
Female 18 55
Male 23 48
Age 0.14
<55 years 16 76
>55 years 25 33
Duration of symptoms 0.53
<6 month 25 52
>6m o n t h s 1 1 0
Unknown 5 50
Histological subtype 0.94
Liposarcoma 22 77
Leiomyosarcoma 7 60
MFH 4 33
Other 8 0
Tumor size 0.26
<5cm 2 100
5–10cm 4 100
10–20cm 18 21
>20cm 17 60
Tumor grade 0.05
Low 17 100
High 24 27
Resection 0.39
R0/R1 38 42
R2 3 50
Resection high-grade tumor only 0.03
R0/R1 22 74
R2 2 44
Radiation therapy 0.40
Yes 19 53
No 22 63
Chemotherapy 0.57
Neo-adjuvant 5 30
Adjuvant 2 —
Both 1 —
None 33 43
Multivariate analysis signiﬁcant for grade (P = .006).
incomplete resection. Our plan was not to simply remove the
tumor. Instead, we removed adjacent organs rather than peel
the tumor oﬀ. The pathology report seldom demonstrated
tumor invasion of the proximate organ, but rather sarcoma
abutment and encroachment. This approach is most similar
to the recent report of complete compartmental resection
with avoidance of tumor spilling [7]. However, complete
surgical resection is often technically challenging and limited
by invasion of adjacent nerves, blood vessels, and organs.
Of the 41 patients with primary retroperitoneal tumors, an
initial complete resection rate of 93% was achieved. To attainSarcoma 5
Table 4: Univariate analysis of prognostic factors for disease-free
survival in 38 patients who underwent complete resection of their
primary retroperitoneal sarcoma.
Variable N 5-year survival (%) P-value
Sex 0.69
Female 16 37
Male 22 12
Age 0.87
<55 years 15 35
>55 years 23 0
Duration of symptoms 0.02
<6 month 22 26
>6m o n t h s 1 1 0
Unknown 5 33
Histological subtype 0.91
Liposarcoma 20 50
Leiomyosarcoma 6 40
MFH 4 33
Other 8 0
Tumor size 0.16
<5cm 2 50
5–10cm 4 0
10–20cm 17 23
>20cm 15 —
Tumor grade 0.84
low 16 0
High 22 28
Radiation therapy 0.29
Yes 19 0
No 19 26
Chemotherapy 0.87
Neo-adjuvant 5 —
Adjuvant 2 33
Both 1 0
None 30 12
a complete resection, contiguous organs were removed in
68%, resulting in an estimated 5-year overall survival of
46%. This is comparable to the recent report in which the
5-year survival for high-grade sarcomas was 50% following
complete resection [7]. This is comparable to other reported
series with results ranging from 35–63% [12, 18]i nw h i c h
complete surgical resection was associated with improved
survival.
Reported prognostic factors for overall survival for
retroperitoneal sarcoma include grade, stage, histology, size,
and margin status [4, 5, 14, 19, 20]. Due to the absence
of early symptoms, failure to diagnose small retroperitoneal
sarcomas remains a major issue. In our study, duration
of symptoms inﬂuenced disease-free survival by univariate
analysis. We also found that grade and complete resection
for high-grade tumors were associated with overall survival
by univariate (P<. 05 and P<. 03) as well as multivariate
analysis (P<. 006). This was also reported by Lewis et al.,
who showed that patients with low-grade tumors had a
median survival of 149 months compared to only 33 months
for high-grade tumors [5]. Therefore, the treatment goal for
patients with initial presentation of retroperitoneal sarcoma
should be complete surgical resection, even if adjacent
normal organs need to be removed [5, 7, 12, 21].
A major challenge in treating retroperitoneal sarcomas
today remains the high rate of local recurrence. Even when
a complete resection has been achieved, local recurrence
is the main site of treatment failure. For patients in our
series who had a complete resection, the 5-year disease-free
survival rate was only 18%. This is a discouraging result
and one that needs further work. Local recurrences, even on
multiple occasions, are still able to be treated by subsequent
surgical resection. We followed our patients closely with
imaging(CT+/orMRI)andlocalrecurrenceswereidentiﬁed
early. This early recognition of recurrence allowed tumor to
be completely removed surgically. Fortunately, we did not
see sarcomatosis or multifocality as a pattern of recurrence
that has been described by others as a potential result of
tumor spill during the initial resection. Sarcomatosis has
am u c hp o o r e rp r o g n o s i s[ 22]. For all patients with local
recurrences a second complete resection was achieved 100%
of the time. This is unusual because only one other series
has reported resection rates for recurrences comparable to
those for initial surgery [9]. Thus, 5-year overall survival
was still 46% despite the fact that 22 patients developed
recurrenttumor.Subsequentsurgerywasabletoreturnthem
to disease-free status and allow survival.
The use of adjuvant therapy to reduce the probability of
recurrence and distant metastases has long been a topic of
dispute. In our series, we were unable to show that radi-
ation therapy or chemotherapy had any signiﬁcant impact
on overall or recurrence-free survival. Other studies have
suggested that adjuvant radiation therapy may decrease the
probability of local recurrence [7, 9, 13, 14]. Newer radiation
techniques including intensity modulated radiation therapy,
respiratory guided therapy, image guided radiation therapy,
proton or heavy ion radiation therapy, and stereotactic
radiation therapy should permit a higher dose of radiation
to be given with less normal tissue toxicity. A clinical trial of
preoperative radiation for retroperitoneal sarcomas has been
completed, and results will hopefully indicate beneﬁt for this
population of patients [23]. The beneﬁts of chemotherapy
for retroperitoneal sarcomas are even less clear. In our series,
chemotherapy was beneﬁcial in only a small number of
patients. Although randomized trials suggest beneﬁt from
adjuvant chemotherapy for extremity sarcomas, no trial
shows a clear improvement in outcome for retroperitoneal
sarcomas [24, 25].
5. Conclusions
In conclusion, our results show that sarcoma tumor grade
andcompleteresectionareimportant prognostic variablesin
patients with primary retroperitoneal sarcomas. Aggressive
complete surgical resection can be done safely in the vast
majority of patients, and, in general is the only eﬀective6 Sarcoma
therapy. It remains the treatment of choice and for patients
with initial and recurrent retroperitoneal sarcoma. The role
of adjuvant radiation and chemotherapy needs to be for
evaluated in multicenter randomized trials. We therefore
recommend that surgery is to be optimized in the care
of patients with retroperitoneal sarcomas. Advancements
in tumor biology and selective targeted therapy should
hopefully result in improved management of retroperitoneal
sarcomas.
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